Canopy’s stock reversed on earnings after seeing a rally sparked by the possibility of marijuana reform in the U.S.

Canadian cannabis producer cuts debt load and shows revenue growth in key segments while pushing ahead with U.S. expansion.

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Be cautious ahead of Canopy Growth Corporation's FQ3 results, as weak financials and low margins may hinder stock performance ...

Canopy Growth Corporation ("Canopy Growth" or the "Company") (TSX: WEED) (Nasdaq: CGC) today announces its financial results ...

Canopy Growth Corp. reported a loss of $121.9 million in its latest quarter compared with a loss of $216.8 million in the ...

Canopy Growth (CGC) stock drops 15% in premarket after the company posted wider Q3 loss due to revenue and gross margin declines. Read more here.

Strong holiday sales drove Storz & Bickel net revenue growth of 19% year-over-year Record quarter for Canada medical cannabis with net revenue increasing 16%; international ...

Shares in Canopy Growth fell sharply Friday morning after the company's loss missed expectations in the fiscal third quarter. Shares fell over 18% to 3.27 Canadian dollars ($2.29).

Reports Q3 revenue C$74.8M vs. C$78.5M last year. “Canopy Growth’s (CGC) third quarter highlights that our business has the right ingredients ...

Canopy Growth Corp. RY-PR-S-T +0.04% reported a loss of $121.9-million in its latest quarter compared with a loss of ...

Aurora Cannabis (NASDAQ: ACB) surged 45% after reporting record earnings, boosting CGC, TLRY, and CRON stocks.